Authors

Latest:

Efficacy and Safety of the DLL3/CD3 T-Cell Engager Obrixtamig in Patients With Extrapulmonary Neuroendocrine Carcinomas With High or Low DLL3 Expression: Results From an Ongoing Phase 1 Trial

Jaume Capdevila, MD, PhD, presents results from a phase 1 study showing that obrixtamig monotherapy achieves a 40% response rate and durable disease control with manageable safety in patients with extrapulmonary neuroendocrine carcinoma, particularly those with high DLL3 expression.

Panagiotis J. Vlachostergios, MD, PhD

Latest:

Antibody-Drug Conjugates Carve Out Space in Urothelial Carcinoma Landscape

Monoclonal antibodies have played a key role in the development of personalized oncology and have proven antitumor activity through multiple mechanisms, including direct transmembrane signaling leading to apoptosis, complement mediated cytotoxicity, antibody-dependent cellular cytotoxicity, and inhibiting tumor vasculature and stroma.

Natasha B Leighl, MD, BSc, MMSc

Latest:

Dr Leighl on Patient Satisfaction and Resource Utilization From PALOMA-3 in NSCLC

Natasha B. Leighl, MD, BSc, MMSc, discusses patient satisfaction and resource utilization results from the phase 3 PALOMA-3 study.

Naomi Adjei, MD, MPH, MSEd

Latest:

Dr Adjei on the Rationale for Opportunistic Salpingectomy for Ovarian Cancer Prevention

Naomi Adjei, MD, MPH, MSEd, discusses an analysis of the cost-effectiveness of opportunistic salpingectomy for the primary prevention of ovarian cancer.

Chetasi Talati, MD

Latest:

Dr. Talati on Rationale for Collecting Real-World Data on Venetoclax/HMA Combos in AML

Chetasi Talati, MD, discusses the design of a chart review study with venetoclax and hypomethylating agents in older patients with newly-diagnosed acute myeloid leukemia.

Manmeet S. Ahluwalia, MD, MBA, FASCO

Manmeet S. Ahluwalia, MD, MBA, FASCO, is the deputy pirector, chief scientific officer, chief of medical oncology, and Fernandez Family Foundation Endowed Chair in Cancer Research at Miami Cancer Institute, which is part of Baptist Health South Florida.

Latest:

Dr Ahluwalia on the Evolution of Precision Medicine in Oncology

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses oncology advances that were highlighted at the Miami Cancer Institute Precision Oncology Symposium.

Steven Maron, MD, MSc

Latest:

Integrating FGFR2b Detection Into Standard Treatment Pathways

Panelists discuss how integrating FGFR2b testing into routine diagnostic workflows will be essential to fully realize the benefits of targeted therapy.

John Michael "JM" Bryant, MD

Latest:

Dr Bryant on the Influence of Germline DNA Repair Mutations on Therapeutic Development in PDAC

John M. Bryant, MD, discusses how identifying germline DNA repair mutations may impact the development of targeted therapy development in PDAC.

David D'Ambrosio, MD

Latest:

Dr. D'Ambrosio on the Rationale of Accelerated Partial Breast Irradiation in HR+ Breast Cancer

David D'Ambrosio, MD, discusses the benefit of utilizing adjuvant accelerated partial breast irradiation, as well as a phase 2 trial investigating robotic stereotactic adjuvant accelerated partial breast irradiation for hormone receptor–positive, postmenopausal, early-stage breast cancer.

Bernard Doger de Spéville, MD, PhD

Latest:

Dr Doger de Spéville on Key Efficacy Findings From Part C of TACTI-002 in HNSCC

Bernard Doger de Spéville, MD, PhD, discusses key findings from part C of the phase 2 TACTI-002 trial of eftilagimod alpha plus pembrolizumab as second-line treatment for patients with head and neck squamous cell carcinoma.

Jonathan M. Gerber, MD

Jonathan M. Gerber, MD, is a member of the faculty in the Department of Medicine at New York University (NYU) Grossman School of Medicine; as well as the chief clinical officer of the NYU Perlmutter Cancer Center.

Latest:

Dr Gerber on the Benefits of p53 IHC Testing for Identifying TP53-Mutant MDS and AML in Underserved Regions

Jonathan M. Gerber, MD, discusses the potential implementation of p53 IHC testing for MDS and AML in regions with limited access to NGS.

Surbhi Sidana, MD

Surbhi Sidana, MD, is an associate professor of medicine and associate director for Clinical Research in the Bone Marrow Transplantation and Cell Therapy Division at Stanford University in California.

Latest:

Dr Sidana on the FDA Approval of Belantamab Mafodotin Plus Vd in R/R Myeloma

Surbhi Sidana, MD, discusses belantamab mafodotin-blmf with bortezomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma.

Nikolai Podoltsev, MD, PhD

Nikolai Podoltsev, MD, PhD, is an associate professor of internal medicine (hematology); Duffy Firm Chief for Education, Department of Internal Medicine; associate director, Hematology/Oncology Fellowship Program, Department of Internal Medicine; clinical director, Malignant Hematology, Department of Internal Medicine, Division of Malignant Hematology, Yale Cancer Center.

Latest:

Dr Podoltsev on Blinatumomab Plus Consolidation Chemotherapy in Older BCR-ABL1–Negative ALL

Nikolai Podoltsev, MD, PhD, discusses the addition of blinatumomab to consolidation chemotherapy in older patients with newly diagnosed BCR-ABL1–negative ALL.

Michelle Chi, MD

Latest:

Assessing Bleeding Disorders: Keys for Hem/Onc Fellows

Michelle Chi, MD and Jennifer R. Green, MD, share practical points for trainees to approach the initial evaluation for a bleeding-disorder patient.

Gregory Peter Kalemkerian, MD

Latest:

Dr Kalemkerian on Unmet Needs With the Use of Chemoimmunotherapy in ES-SCLC

Gregory Peter Kalemkerian, MD, discusses the unmet needs associated with the investigation of combination chemoimmunotherapy in the frontline treatment of patients with extensive-stage small cell lung cancer.

Nelli Bejanyan, MD

Latest:

OncLive Peer Exchange on Allo-HSCT: Conclusion of Discussion

The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.

Kersti Oselin, MD, PhD

Latest:

Dr Oselin on a Subgroup Analysis of the PEARLS/KEYNOTE-091 Trial in NSCLC

Kersti Oselin, MD, PhD, discusses a subgroup analysis from the phase 3 PEARLS/KEYNOTE-091 study of pembrolizumab in patients with early-stage non‒small-cell lung cancer following resection.

Lindsay L. Kroener, MD

Latest:

Dr. Kroener on Utilizing Embryo Cryopreservation in Breast Cancer

Lindsay L. Kroener, MD, discusses fertility preservation in patients with breast cancer.

Kun-Hsing Yu, MD, PhD

Kun-Hsing Yu, MD, PhD, is an associate professor of Biomedical Informatics at Harvard Medical School, an assistant professor of pathology at Brigham and Women's Hospital, and an instructor in epidemiology at Harvard T.H. Chan School of Public Health.

Latest:

The Future of Pathology With AI: Predicting Prognosis and Personalized Treatment

Payal D. Shah

Latest:

Dr. Shah on the Significance of PARP Inhibitors in Ovarian Cancer

Payal D. Shah, MD, discusses the significance of the emergence of PARP inhibitors in ovarian cancer.